Diverse Biotech, Inc. is an innovative, clinical-stage biopharmaceutical research company that is
committed to discovering and developing novel therapeutics from its proprietary and patented cannabinoid
formulations and cancer research. The Company’s formulas are novel discoveries for improving the
health and well-being of cancer patients around the world.
Diverse Pharma, Diverse DNA, Diverse Hydro and Maximum Brands are wholly owned subsidiaries of the parent company, Diverse Biotech. Each are focused on improving health and wellness through a variety of products from cancer DNA prescreening to nutraceuticals and supplements. Led by an experienced executive team that includes Stella Vnook (CEO), Dr. Philip Arlen (CSO) Louis Olave (VP) and Beaudon Spaulding (VP). The Company Board of Directors includes a committee of medical advisors who are among the top cancer treatment opinion leaders in the world.
BRCX is a very promising set of drug compounds in the Diverse pipeline. Diverse Biotech’s proprietary cannabinoid formulas are being tested as sublingual/oral formulations for the treatment of breast, colorectal, pancreatic, myeloma, glioblastoma and gallbladder cancers, among others. While this testing is taking place, the Company is rapidly expanding its IP as new discoveries are identified in oncology and related diseases.